Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2499-2506

  Terakura, Daishi ^a   Shimizu, Masahito ^a   Iwasa, Junpei ^a   Baba, Atsushi ^a   Kochi, Takahiro ^a   Ohno, Tomohiko ^a   Kubota, Masaya ^a   Shirakami, Yohei ^a   Shiraki, Makoto ^a   Takai, Koji ^a   Tsurumi, Hisashi ^a   Tanaka, Takuji ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BRANCHED CHAIN AMINO ACID; CASEIN; CYCLIN D1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NITROGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN C FOS; PROTEIN P21; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; HEPATIC PRENEOPLASTIC LESION; LIVER CANCER; LIVER CARCINOGENESIS; MALE; MONOCYTE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; CYTOKINES; DIETARY SUPPLEMENTS; INSULIN RESISTANCE; LIVER; LIVER NEOPLASMS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PPAR GAMMA; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-FOS; RNA, MESSENGER;

EID: 84870348582     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs303     Document Type: Article

References (42)

1. El-Serag, H.B. et al. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.
2. Sun, B. et al. (2012) Obesity, inflammation, and liver cancer. J. Hepatol., 56, 704-713.
3. Muto, Y. et al. (2006) Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res., 35, 204-214.
4. Imai, K. et al. (2010) Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol. Res., 40, 376-382.
5. El-Serag, H.B. et al. (2001) The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am. J. Gastroenterol., 96, 2462-2467.
6. Siegel, A.B. et al. (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer, 115, 5651-5661.
7. Ratziu, V. et al. (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology, 35, 1485-1493.
8. Smedile, A. et al. (2005) Steatosis and hepatocellular carcinoma risk. Eur. Rev. Med. Pharmacol. Sci., 9, 291-293.
9. Powell, E.E. et al. (2005) Steatosis: co-factor in other liver diseases. Hepatology, 42, 5-13.
10. Park, E.J. et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 140, 197-208.
11. Shimizu, M. et al. (2012) Nutraceutical approach for preventing obesityrelated colorectal and liver carcinogenesis. Int. J. Mol. Sci., 13, 579-595.
12. Moriwaki, H. et al. (2004) Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem. Biophys. Res. Commun., 313, 405-409.
13. Kawaguchi, T. et al. (2011) Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology, 54, 1063-1070.
14. Muto, Y. et al. (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol., 3, 705-713.
15. Marchesini, G. et al. (2003) Nutritional supplementation with branchedchain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology, 124, 1792-1801.
16. Kawaguchi, T. et al. (2008) Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int. J. Mol. Med., 22, 105-112.
17. Iwasa, J. et al. (2010) Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci., 101, 460-467.
18. Shimizu, M. et al. (2009) Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin. Cancer Res., 15, 3068-3075.
19. Hagiwara, A. et al. (2012) Branched-chain amino acids prevent insulininduced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J. Cell. Physiol., 227, 2097-2105.
20. Arakawa, M. et al. (2011) The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. Endocr. J., 58, 161-170.
21. Weisberg, S.P. et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 1796-1808.
22. Xu, H. et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest., 112, 1821-1830.
23. Li, P. et al. (2005) Metabolic and cellular plasticity in white adipose tissue II: role of peroxisome proliferator-activated receptor-alpha. Am. J. Physiol. Endocrinol. Metab., 289, E617-E626.
24. Tsuchida, A. et al. (2005) Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes, 54, 3358-3370.
25. Ouchi, N. et al. (2007) Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta, 380, 24-30.
26. Frith, C.H. et al. (1994) Tumours of the liver. In Pathology of Tumors in Laboratory Animals. Vol. 2. IARC Scientific Publications, Lyon, pp. 223-270.
27. Suzuki, R. et al. (2007) Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int. J. Cancer, 120, 252-258.
28. Shimizu, M. et al. (2011) Pitavastatin suppresses diethylnitrosamineinduced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer, 11, 281.
29. FOLCH, J. et al. (1957) A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem., 226, 497-509.
30. Kamei, N. et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem., 281, 26602-26614.
31. Kanda, H. et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest., 116, 1494-1505.
32. Yu, J. et al. (2010) Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology, 51, 2008-2019.
33. Koga, H. et al. (2001) Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology, 33, 1087-1097.
34. Yang, S. et al. (2001) Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res., 61, 5016-5023.
35. Shimizu, M. et al. (2011) Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-+(db)/+Lepr(db) mice. Cancer Prev. Res. (Phila)., 4, 128-136.
36. Shimizu, M. et al. (2011) Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice. Cancer Prev. Res. (Phila)., 4, 396-403.
37. Clément, S. et al. (2008) Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology, 48, 799-807.
38. Yamauchi, T. et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem., 276, 41245-41254.
39. Kamada, Y. et al. (2007) Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol., 47, 556-564.
40. Xu, A. et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest., 112, 91-100.
41. Reddy, J.K. et al. (1976) Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res., 36, 1211-1217.
42. Yoshiji, H. et al. (2009) Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J. Gastroenterol., 44, 483-491.